Eli Lilly's weight-loss drug could be the best selling drug of all time, says Jim Cramer

Eli Lilly's weight-loss drug could be the best selling drug of all time, says Jim CramerПодробнее

Eli Lilly's experimental obesity drug could be 'revolutionary,' says Jim CramerПодробнее

Jim Cramer explains why he favors Eli Lilly in the weight loss drug spaceПодробнее

Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugsПодробнее

Eli Lilly could have the 'biggest drug in history' in its pipeline, says Jim CramerПодробнее

Eli Lilly and Novo can 'coexist for awhile' in the weight-loss drug space, says BMO's Evan SeigermanПодробнее

Cramer’s Mad Dash: Eli LillyПодробнее

Eli Lilly seeks FDA approval for weight loss drug tirzepatideПодробнее

Exclusive: How Eli Lilly’s making weight loss drugs more accessibleПодробнее

Eli Lilly stock soars on earnings, 'off-the-charts' demand for weight-loss drugsПодробнее

Eli Lilly releases new data from potentially game-changing weight loss drug trialПодробнее

Potential for Weight-Loss Drugs Boosts Eli LillyПодробнее

Eli Lilly's obesity drug will be a tailwind for the stock, says BMO's Evan SeigermanПодробнее

Eli Lilly CEO on weight loss drugs outlook: Our top priority is making more productПодробнее

I get stories every day from patients about how Mounjaro is benefiting their lives: Eli Lilly CEOПодробнее

Eli Lilly CEO David Ricks on GLP-1 and obesity drugsПодробнее

Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugsПодробнее

We stuck with Eli Lilly because we did the homework, says Jim CramerПодробнее

Eli Lilly drug tirzepatide meets weight-loss goals in obesity trialПодробнее

Jim Cramer says there's a buying opportunity in this pharmaceutical companyПодробнее